Answers are grounded in this paper and cite their sources.
BACKGROUND & AIMS: We investigated whether liver disease alters HSD17B13 isoform expression, identifying selective loss of exon 2-skipped variants and uncovering variant B as a structured, noncoding RNA with silencing potential. METHODS: Human liver samples from lean control (n = 6), metabolic dysfunction-associated steatotic liver (MASL, n = 8), and metabolic dysfunction-associated steatohepatitis (MASH, n = 8) participants were analyzed by isoform-specific reverse-transcription PCR and quantitative PCR. HepG2 cells were transfected with HSD17B13 variant A or B constructs. RNA expression, protein production, RNase sensitivity, and RNA structural conformations (RNAfold) were evaluated. Functional effects were tested under oleic acid-induced lipotoxic stress. RESULTS: We observed a selective reduction in exon 2-skipped HSD17B13 isoforms (variants B and G) in both human MASL (∼63% vs. lean control; p <0.01) and MASH (∼93% vs. lean control; p <0.001), independent of rs72613567:TA genotype. Notably, variant B nearly abolished endogenous HSD17B13 expression in HepG2 cells (∼99% reduction; p <0.001) without generating detectable protein. RNase III sensitivity assays and RNAfold modeling revealed stable, duplex-rich RNA structures, supporting a noncoding regulatory role for these isoforms under oleic acid-induced lipotoxic stress. CONCLUSIONS: Restoration of exon 2-skipped HSD17B13 isoforms, particularly variant B, may offer a genotype-independent therapeutic strategy for MASH by mimicking protective effects through structured RNA-mediated suppression of enzymatic HSD17B13 activity. IMPACT AND IMPLICATIONS: These findings support a dual mechanism of HSD17B13 regulation in liver disease through genotype-mediated transcript suppression and disease-driven isoform imbalance. Therapeutic re-expression of exon 2-skipped isoforms, particularly variant B, may offer a novel strategy to replicate the protective effect of the TA allele without enzymatic inhibition.
No takes yet. Share an insight, caveat, or question.
Min et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: